Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, announced today that Gregory T. Lucier has been appointed as a corporate advisor. In the role, Mr. Lucier will advise Chief Executive Officer Keith Murphy and the executive management team on various corporate issues.
"As Organovo moves towards launch of a major new offering, our 3D Human Liver Tissue, we have been putting the pieces in place to execute on our opportunity and deliver results to shareholders," stated Organovo Chief Executive Officer Keith Murphy. "We have been hiring for key roles, building the necessary internal processes, and driving our scientists to finalize the tissue production and testing protocols. Bringing on someone who can assist the company in our launch stage and during our commercial growth is critical. Given his tremendous track record of success at Life Technologies, no one is better for this role than Greg Lucier."
"I'm pleased to be asked to help the executive management of Organovo deliver on the promise of three dimensional bioprinting," said Greg Lucier. "As I have learned more about Organovo's team and technology, it's clear there is a compelling opportunity to advance their early scientific performance into strong commercial wins. I look forward to using my leadership experience, strategic thinking in the life sciences industry, and track record bringing biomedical commercial solutions to market, to help guide the company in its next phase."
Mr. Lucier was formerly Chairman and CEO of Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific for $15.6.billion in 2014. During Mr. Lucier's 11-year tenure at Life Technologies, he led the company from a small start-up known as Invitrogen in 2003, directed the acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the renamed Life Technologies, and then transformed the organization by 2013 into a global, world-leading biotechnology firm with 50,000 products, 12,000 employees and nearly $4 billion in sales in more than 180 countries. Serving in his leadership role, Mr. Lucier was responsible for fostering a culture of excellence at Life Technologies, and applied his more than 25 years of strategic management experience to help champion an era of personalized medicine.
Prior to his tenure at Life Technologies, Mr. Lucier was a corporate officer of General Electric Company where he served in a variety of leadership roles. Mr. Lucier received a bachelor's degree in engineering with honors from Pennsylvania State University, and an MBA from Harvard Business School. He serves on the boards of NuVasive Corporation, RainTree Oncology Services, CareFusion, and is board chairman for Sanford Burnham Medical Research Institute.
